Experimental Compounds Obliterate Liver Fat When Drugs Failed Completely

Person holding multiple blister packs of pills — SHOCKING DRUG NEWS

Cannabis compounds CBD and CBG show promise in reversing MASLD, a liver disease plaguing one-third of adults amid America’s obesity crisis fueled by years of failed leftist health policies.

Story Highlights

Hebrew University study reveals CBD and CBG reduce liver fat and boost metabolic health in experimental models, targeting a condition affecting 33% of global adults.
CBG outperforms CBD in cutting body fat, LDL cholesterol, and improving insulin sensitivity, offering hope beyond scarce pharmaceutical options.
Preclinical findings highlight novel mechanisms like energy buffering and lysosomal revival, with no human trials yet.
Breakthrough aligns with expanding medical cannabis research, potentially lowering opioid reliance and healthcare costs.

Breakthrough in MASLD Treatment

Prof. Joseph Tam’s team at Hebrew University of Jerusalem published research in the British Journal of Pharmacology showing cannabidiol (CBD) and cannabigerol (CBG) reverse Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

This chronic condition features excess liver fat from metabolic issues, impacting about one-third of adults worldwide and 4.5 million Americans. Tied to obesity, diabetes, and insulin resistance, MASLD lacks approved drugs, forcing reliance on lifestyle changes.

The study used experimental models to demonstrate these non-psychoactive compounds reduce liver fat through metabolic remodeling.

Compounds found in cannabis could provide a new roadmap for treating the world’s most common chronic liver disorder, according to a study released by the Hebrew University of Jerusalem. https://t.co/lK3IWNoEYO

— FOX6 News (@fox6now) March 10, 2026

Mechanisms and Superior Effects of CBG

CBD and CBG enhance liver energy reserves via a “backup battery” mechanism involving phosphocreatine and lysosomal cathepsins, bypassing traditional cannabinoid receptors. CBG proved superior, significantly lowering body fat, LDL cholesterol, and boosting insulin sensitivity compared to CBD.

Prof. Tam noted this reveals a completely new way cannabinoids protect the liver, with potential extensions to diabetes and obesity. These plant-based approaches address unmet needs in metabolic diseases long ignored by big pharma’s profit-driven models.

Preclinical Status and Research Context

The study remains in preclinical stages using experimental models, with no human trials reported as of March 2026. Media coverage peaked around March 6-10, following early 2026 publication.

This builds on decades of cannabis research showing anti-inflammatory and metabolic benefits, including FDA-approved uses for nausea and seizures. Recent 2026 trials confirm CBG and CBD roles in reducing neuroinflammation, chronic pain by 30-70%, and opioid needs in medical cannabis states.

Broader Implications for Health and Policy

If validated clinically, these findings could restore metabolic flexibility for liver disease, diabetes, obesity, and neurodegeneration patients. Short-term, expect shifts toward cannabis trials, reducing lifestyle-only dependence, though media hype risks unverified supplement claims.

Long-term, broader medical cannabis adoption may cut healthcare costs via opioid reduction and grow the CBG market. This advances de-stigmatization, challenging FDA caution on non-approved uses while reinforcing individual liberty in health choices over government overreach.

Cannabis compounds could reverse disease affecting one-third of adults https://t.co/UxUFPj2X9V pic.twitter.com/m3CcA47npo

— New York Post (@nypost) March 10, 2026

Expert Views and Limitations

Prof. Tam emphasized CBD and CBG reprogram cellular metabolism, boosting energy and clearing fats, with CBG’s potency in fat and LDL reduction. CompCareMD experts highlight cannabis outperforming anti-nausea drugs and aiding Alzheimer’s.

JAMA reviews affirm strong evidence for approved uses but caution on broader applications. Sources agree on promise yet stress human trial needs; Tam’s specialized center lends credibility amid preclinical limits.